search
Back to results

Donepezil HCl & Cognitive Deficits in Autism

Primary Purpose

Autistic Disorder

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Donepezil HCl
Placebo
Sponsored by
University of Pittsburgh
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Autistic Disorder

Eligibility Criteria

8 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Autism Spectrum Disorder (ASD) Asperger's Disorder IQ of 75 or above Baseline assessment tests within the acceptable range Exclusion Criteria: Bipolar disorder, schizophrenia, schizoaffective disorder, or psychotic disorder Seizure disorder requiring the use of anticonvulsant medications Congenital rubella, cytomegalovirus, or tuberous sclerosis Certain medications prescribed for management of behavior (please contact the investigator for a complete list) Medications/preparations that are known to interact with donepezil HCl Significant medical illness, endocrinopathies, cardiovascular disease, or severe chronic malnutrition Pregnancy or sexually active females not using a reliable method of contraception

Sites / Locations

  • Western Psychiatric Institute & Clinic

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Donepezil HCl

Placebo

Arm Description

Donepezil HCL 5 mg and 10 mg

Placebo

Outcomes

Primary Outcome Measures

Cognitive Assessment: TMT
TMT: Trial-Making Test. Time (sec) Range: 0 - 300. Lower = better
Cognitive Assessment: EOWVT Standard Score
Expressive One Word Vocabulary Test (standard score) Range: 55-140. Higher = better
Cognitive Assessment: CVLT
California Verbal Learning Test (percent of correct answers) Range: 0-100. Higher = better

Secondary Outcome Measures

Full Information

First Posted
October 11, 2002
Last Updated
September 7, 2017
Sponsor
University of Pittsburgh
Collaborators
National Institute of Mental Health (NIMH)
search

1. Study Identification

Unique Protocol Identification Number
NCT00047697
Brief Title
Donepezil HCl & Cognitive Deficits in Autism
Official Title
Donepezil HCl: Treating Cognitive Deficits in Autism
Study Type
Interventional

2. Study Status

Record Verification Date
September 2017
Overall Recruitment Status
Completed
Study Start Date
October 2002 (undefined)
Primary Completion Date
August 2006 (Actual)
Study Completion Date
August 2006 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Pittsburgh
Collaborators
National Institute of Mental Health (NIMH)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This 11-week study will examine the safety and effectiveness of the medication donepezil (Aricept®) compared to placebo for treating cognitive deficits in children and adolescents with Autism Spectrum Disorder.
Detailed Description
Children with autism spectrum disorder (ASD) often have impaired communication, problems with social interaction, and repetitive and stereotyped patterns of behavior. While most research has attempted to treat the behavioral deficits commonly associated with ASD, few studies have attempted to improve the core features of this disorder. A recent study found that donepezil HCl helped to improve speech production, attention span, and ability to express emotions in a group of children with autism. This study will provide an opportunity to conduct further testing of the effects of donepezil HCl on the cognitive deficits presumed to underlie the core features of ASD. This study begins at Week 1 with a baseline assessment. Participants are then randomly assigned to either donepezil HCl or placebo. Participants will start with either a 5mg/day dose of donepezil HCl or placebo followed by a cognitive assessment after 4 weeks on this dose. Participants will then have their dose increased to 10mg/day. Another cognitive assessment will be given after 4 weeks on this dose.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Autistic Disorder

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
34 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Donepezil HCl
Arm Type
Experimental
Arm Description
Donepezil HCL 5 mg and 10 mg
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Drug
Intervention Name(s)
Donepezil HCl
Other Intervention Name(s)
Aricept
Intervention Description
Participants will start with 5 mg per day dose of donepezil HCl, then have their dose increased to 10mg per day after 4 weeks.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo used in placed of Donepezil HCL
Primary Outcome Measure Information:
Title
Cognitive Assessment: TMT
Description
TMT: Trial-Making Test. Time (sec) Range: 0 - 300. Lower = better
Time Frame
8 weeks
Title
Cognitive Assessment: EOWVT Standard Score
Description
Expressive One Word Vocabulary Test (standard score) Range: 55-140. Higher = better
Time Frame
8 weeks
Title
Cognitive Assessment: CVLT
Description
California Verbal Learning Test (percent of correct answers) Range: 0-100. Higher = better
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Autism Spectrum Disorder (ASD) Asperger's Disorder IQ of 75 or above Baseline assessment tests within the acceptable range Exclusion Criteria: Bipolar disorder, schizophrenia, schizoaffective disorder, or psychotic disorder Seizure disorder requiring the use of anticonvulsant medications Congenital rubella, cytomegalovirus, or tuberous sclerosis Certain medications prescribed for management of behavior (please contact the investigator for a complete list) Medications/preparations that are known to interact with donepezil HCl Significant medical illness, endocrinopathies, cardiovascular disease, or severe chronic malnutrition Pregnancy or sexually active females not using a reliable method of contraception
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Benjamin L. Handen, PhD
Organizational Affiliation
University of Pittsburgh, School of Medicine, Department of Psychiatry
Official's Role
Principal Investigator
Facility Information:
Facility Name
Western Psychiatric Institute & Clinic
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
We have no specific plan to share data at this time.

Learn more about this trial

Donepezil HCl & Cognitive Deficits in Autism

We'll reach out to this number within 24 hrs